Silexion published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 11.91 million. Research and development expense rose 22.4% to USD 7.14 million, mainly due to higher subcontractor and consultant costs tied to GMP API batches and formulation work ahead of a planned human clinical trial expected in Q2 2026, contingent on regulatory clearance. General and administrative expense fell 33.8% to USD 4.49 million, driven mainly by lower non-cash share-based compensation, partly offset by higher professional services costs related to operating as a public company. Net cash used in operating activities increased 28.6% to USD 10.82 million, while cash and cash equivalents totaled USD 6.0 million as of Dec. 31, 2025. Management said current cash is expected to fund operations for only several months from the filing date and that additional capital will be needed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000953), on March 17, 2026, and is solely responsible for the information contained therein.
Comments